---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-260417"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T23:05:57.604544+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Intellia Phase 1 in vivo CRISPR therapy nex-z shows disease stabilization in ATTR amyloidosis

## Summary
- Single dose of nex-z achieved mean 90% serum TTR reduction at month 12 in ATTR-CM (n=36); sustained >24 months.
- 81% of ATTR-CM patients stable/improved in NT-proBNP, 94% in hs-Troponin T at month 12; hospitalization rate 0.16/yr.
- In ATTRv-PN, mean TTR reduction 91% at month 12 (n=33); neuropathy scores stable or improved through month 24.
- Favorable safety: infusion-related reactions mild/moderate, no discontinuations; Phase 3 MAGNITUDE trials ongoing.
- Data published in NEJM and presented at AHA 2024; supports hypothesis greater TTR reduction yields greater clinical benefit.

## SEC filing metadata
- accession: 0001193125-24-260417
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312524260417/0001193125-24-260417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312524260417/d828128d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-260417
- JSON: https://secwatch.observer/filing/0001193125-24-260417.json
- Plain text: https://secwatch.observer/filing/0001193125-24-260417.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.